A snapshot of Chimeric’s (ASX:CHM) exclusive global licence for CORE-NK platform - Kalkine Media

Highlights

• Chimeric has executed an exclusive licence agreement with Case Western Reserve University (CWRU) for the CORE-NK platform.
• The agreement provides exclusive worldwide rights to Chimeric for the CORE-NK platform for oncology.
• CHM 0201, Chimeric’s NK cell therapy portfolio foundational asset, has demonstrated promising results in a phase 1 clinical trial focused on blood cancers and solid tumours.

Australian leader in cell therapy Chimeric Therapeutics (ASX:CHM) is making major headways in its clinical development pipeline.

Last month, the clinical-stage cell therapy company executed an exclusive licence agreement with Case Western Reserve University (CWRU) for the CORE-NK platform.

The development provides exclusive global rights to Chimeric for the CORE-NK platform for oncology. The platform, invented by Dr David Wald, utilises a novel, exclusive genetically modified feeder cell line to stimulate and boost universal off-the-shelf allogeneic NK cell products developed from healthy donors. 

The agreement builds the base for a suite of next-generation genetically modified NK cell products, said Jennifer Chow, CEO and Managing Director of Chimeric.

© 2022 Kalkine Media®, Data source: Company update

Chimeric will fund upfront fees related to the licence agreement entirely from existing cash reserves. The agreement also includes costs of patent, maintenance fees, industry-standard development milestones and royalties on net commercial sales.

Sponsored research agreement with CWRU

Chimeric recently announced a sponsored research agreement with CWRU, under which both parties are advancing multiple product candidates in Dr Wald’s laboratory.

The company has also gained exclusive global rights to the CORE-NK platform for immune disorders and viral infectious diseases.

Initial clinical study indicated safety

CHM 0201, Chimeric’s foundational asset under the NK cell therapy portfolio, was studied in a phase 1 clinical trial at University Hospitals Seidman Cancer Center in Ohio that demonstrated promising clinical results. The results were published in the journal "Transplantation and Cellular Therapy" in early 2022.

The results indicated safety with no graft versus host disease (GvHD), NK cell persistence for a minimum of 28 days, and encouraging early activity signals, especially in blood cancers. All the patients achieved disease control, and one patient achieved a complete response that was sustained for more than 15 months at the time of study publication.

Based on the initial activity signal, a new clinical trial has been commenced using the CORE NK cells (CHM 0201) in combination with Vactosertib.

© 2022 Kalkine Media®, Data source: Company update

On 20 December 2022, shares of Chimeric traded at AU$0.079.